Objective. Literature review and subsequent gap analysis of the current Alberta Cancer Board (ACB) Oncology Medication Error Prevention Status Survey and the incorporation of new information to aid in the development of a stronger medication error prevention system.
Design. Gap analysis based on a literature review was performed on the current ACB survey via a literature search of EMBASE, Medline, and the Cochrane Database of Systematic Reviews. The completed survey was sent to 17 ACB sites for feedback.
Setting. The ACB in the Canadian province of Alberta, which includes 2 public tertiary centers and 15 associated community satellite sites based around the province in existing hospitals.
Main outcome measures. Gaps in the current medication error prevention survey requiring improvement as compared to current literature, with emphasis on pharmacy.
Results. All sections required additional information and two new sections were created to reduce the gaps in organizational commitment and environmental concerns. Of the 17 ACB sites, 13 sites responded to the survey and 11 responded to the questionnaire. Out of a possible 154 questions, 64 questions had at least one site disagree and 20 questions had more than one site disagree.
Conclusion. Through a literature review and gap analysis, the current ACB Oncology Medication Error Prevention Status Survey was improved. Responses to changes have not only demonstrated the need for a survey of this kind, but also the need for periodic updates of the information in the survey.
Kohn LT, Corrigan JM, Donaldson MS, eds. To err is human: building a safer health system. Washington, DC: National Academy Press, 1999.
2.
Phillips J, Beam S, Brinker A, et al.Retrospective analysis of mortalities associated with medication errors. Am J Health-Syst Pharm2001; 58: 1835-1841.
3.
Beckwith MC, Tyler LS.Preventing medication errors with antineoplastic agents, Part I. Hosp Pharm2000; 35: 511-525.
4.
Beckwith MC, Tyler LS.Preventing medication errors with antineoplastic agents, Part II. Hosp Pharm2000; 35: 732-747.
5.
Bauman AN, Pedersen CA, Schommer JC, Griffith NL.Policies on documentation and disciplinary action in hospital pharmacies after a medication error. Am J Health-Syst Pharm2001; 58: 1120-1125.
6.
Bates DW, Cullen DJ, Laird N, et al.Incidence of adverse drug events and potential adverse drug events. Implications for prevention. ADE Prevention Study Group. JAMA1995; 274: 29-34.
7.
Peartree Solutions. A situational analysis of human resource issues in the pharmacy profession in Canada. Executive summary. Hum Resour Dev Can. Government of Canada, May 2002.
8.
Bridge Medical Medication error prevention program: checklist for hospitals. Bridge Medical [www.mederrors.com; accessed 10 May 2002].
9.
Medication safety self-assessment for community/ambulatory pharmacy. Institute for Safe Medication Practices [www.ismp.org.; accessed 10 May 2002].
10.
Appendix A. Guidelines for liability and risk management. CSHP Off Publ [www.cshp.org; accessed 15 May 2002].
11.
Ross TW, Wojdylo JR.Identifying sources and reducing the potential for chemotherapy-related errors: mission impossible?JMCC1997; 4: 528-536.
12.
Mahoney CD, Berard CM, Simas EA, Lacroix S, Mahoney GM.Implementing a chemotherapy practice standard in an integrated health care system. Hosp Pharm1998; 33: 954-960.
13.
Fischer DS, Alfano M, Knobf MT, Donovan C, Beaulieu N.Improving the cancer chemotherapy use process. J Clin Oncol1996; 12: 3148-3155.
14.
Gilbar PJ.Cancer chemotherapy: potential errors with external referrals. Aust J Hosp Pharm1999; 29: 100-102.
15.
Dunn EB, Wolfe JJ.Medication error reduction: the pharmacy technician’s role. J Pharm Technol1998; 14: 70-77.
16.
Cohen MR.Drug product characteristics that foster drug-use-system errors. Am J Health-Syst Pharm [www.ashp.org/public/proad/mederror/pcoh.html; accessed 11 May 2002].
17.
Argo AL, Cox KK, Kelly WN.The ten most common lethal medication errors in hospital patients. Hosp Pharm2000; 35: 470-474.
18.
Kelly WN. Pharmacy contributions to adverse medication events [www.ashp.org/public/proad/mederror/pkel.html; accessed 10 May 2002].
19.
Gilmore CE, Suresky P.Development and implementation of a chemotherapy error-prevention policy. Hosp Pharm1998; 33: 1213-1218.
20.
Massachusetts Coalition for the Prevention of Medical Errors. MHA best practice recommendations to reduce medication errors [www.mhalink.org/mcpme/mha_best_practice_recommendation.htm; accessed 17 October 2001].
21.
Goldspiel BR, DeChristoforo R, Daniels CE.A continuous-improvement approach for reducing the number of chemotherapy-related medication errors. Am J Health-Syst Pharm2000; 57(Suppl 4): S4-S9.
22.
Berwick DM.Lessons from a novice. Presented at ‘Let’s Talk: Communicating Risk and Safety in Health Care’. Institute for Safe Medication Practices [www.ismp.org/pages/patientsafety.html; accessed 11 December 2001].
23.
Hutcherson DA, Gammon DC.Preventing errors with antineoplastic agents: a pharmacist’s approach. Hosp Pharm1997; 32: 194-202, 209-209.
24.
Leape LL, Cullen DJ, Clapp MD, et al.Pharmacist participation on physician round and adverse drug events in the intensive care unit. JAMA1999; 282: 267-270.
25.
US Pharmacopeia. Use caution -avoid confusion. USP Qual Rev2001; 76: 1-6.
26.
Leape LL.Preventing adverse drug events (from Understanding and Preventing Drug Misadventures Conference) [www.ashp.org/public/proad/mederrors/plea.html; accessed 5 November 2001].
Crane VS.New perspectives on preventing medication errors and adverse drug events. Am J Health-Syst Pharm2000; 57: 690-697.
29.
Kohn, LT.The Institute of Medicine report on medical errors: overview and implications for pharmacy. Am J Health-Syst Pharm2001; 58: 63-66.
30.
US Pharmacist. Preventing medication error. US Pharmacist Continuing Education [www.uspharmacist.com/newlook/ce/medErrors/lesson.cfm; accessed 12 February 2001].
31.
Senders J.Theory and analysis of typical errors in a medical setting. Hosp Pharm1993; 28: 505-508.
32.
Gattis WA, Hasselblad V, Whellan DJ, O’Connor CM.Reduction in heart failure events by the addition of a clinical pharmacist to the heart failure management team. Arch Intern Med1999; 159: 1939-1945.
33.
Schneider PJ.Pharmacists building a safer health system. Am J Health-Syst Pharm2001; 58: 66-68.
34.
Cohen MR, Anderson RW, Attilo RM, Green L, Muller RJ, Pruemer JM.Preventing medication errors in cancer chemotherapy. Am J Health-Syst Pharm1996; 53: 737-746.
35.
Olson KM.Medication errors: problems identified, but what is the solution?Crit Care Med2002; 30: 1-3.
36.
American Society of Health System Pharmacists. ASHP statement on reporting medical errors. Am J Health-Syst Pharm2000; 57: 1531-1532.
37.
Trinkle R, Wu JK.Errors involving pediatric patients receiving chemotherapy: a literature review. Med Pediatr Oncol1996; 26: 344-351.
38.
Proulx S, Wilfinger R, Cohen MR.Medication error prevention: profiling one of pharmacies foremost advocacy efforts for advice on error prevention. Pharm Pract Manag Q1997; 17: 1-9.
